Serum Soluble Fas Level Determines Clinical Outcome of Patients with Diffuse Large B-cell Lymphoma Treated with CHOP and R-CHOP

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2009 Apr 22

PMID 19381687

Citations 6

Authors

Takeshi Hara

Hisashi Tsurumi

Naoe Goto

Nobuhiro Kanemura

Takeshi Yoshikawa

Senji Kasahara

Toshiki Yamada

Michio Sawada

Hideko Goto

Kenji Fukuno

Jun-ichi Kitagawa

Ichiro Yasuda

Naoki Katsumura

Masao Takemura

Takeshi Takahashi

Tsuyoshi Takami

Hisataka Moriwaki

Affiliations

Soon will be listed here.

Abstract

Introduction: We previously reported that serum concentrations of soluble Fas (sFas) predict the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) after treatment with CHOP but without rituximab (R). Here, we investigated whether the role of sFas as a prognostic factor remains valid in the R-CHOP era.

Patients: We treated 132 patients with DLBCL between October 1995 and September 2002 (group A: without rituximab), and 75 between December 2002 and March 2007 (group B: with rituximab). The patients received eight cycles of CHOP or THP (tetrahydropyranyl-adriamycin)-COP before September 2002, and R-CHOP or R-THP-COP after October 2002. The distribution of patients according to the International Prognostic Index did not significantly differ between the groups.

Results: The 5-year overall survival (OS) rates for patients with sFas levels of > or = 3.0 and <3.0 ng/ml in group A were 19.8 and 61.9% (P < 0.0001), whereas the 3-year OS rates in group B were 54.7 and 92.2% (P < 0.01), respectively. Multivariate analysis using the proportional hazards model revealed that sFas most significantly correlated with overall survival (P < 0.05).

Conclusion: Serum sFas is thus a useful tool for selecting the appropriate therapeutic strategy for DLBCL.

Citing Articles

Clinical significance of oxidative stress for untreated patients with diffuse large B-cell lymphoma.

Nakamura H, Hara T, Mabuchi R, Matsumoto T, Nakamura N, Ninomiya S Mol Clin Oncol. 2021; 16(1):4.

PMID: 34824844 PMC: 8609529. DOI: 10.3892/mco.2021.2437.

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

de Charette M, Houot R Haematologica. 2018; 103(8):1256-1268.

PMID: 30006449 PMC: 6068015. DOI: 10.3324/haematol.2017.184192.

Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure.

Podd B, Simon D, Lopez S, Nowalk A, Aneja R, Carcillo J Pediatr Clin North Am. 2017; 64(5):1071-1088.

PMID: 28941536 PMC: 5663307. DOI: 10.1016/j.pcl.2017.06.007.

Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Taylor J, Gribben J Semin Cancer Biol. 2015; 34:36-45.

PMID: 26232774 PMC: 4592463. DOI: 10.1016/j.semcancer.2015.07.004.

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C J Hematol Oncol. 2015; 8:70.

PMID: 26071053 PMC: 4472251. DOI: 10.1186/s13045-015-0168-7.

References

Cheng J, Zhou T, Liu C, Shapiro J, BRAUER M, Kiefer M . Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263(5154):1759-62. DOI: 10.1126/science.7510905. View

Suda T, Takahashi T, Golstein P, Nagata S . Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993; 75(6):1169-78. DOI: 10.1016/0092-8674(93)90326-l. View

Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

Griffith T, Brunner T, Fletcher S, Green D, Ferguson T . Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995; 270(5239):1189-92. DOI: 10.1126/science.270.5239.1189. View

. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982; 49(10):2112-35. DOI: 10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2. View

Miller A, SALEWSKI E . Prospects for pirarubicin. Med Pediatr Oncol. 1994; 22(4):261-8. DOI: 10.1002/mpo.2950220410. View

Takagi T, Oguro M . (2"-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol. 1987; 20(2):151-4. DOI: 10.1007/BF00253970. View

Shipp M, Abeloff M, Antman K, Carroll G, Hagenbeek A, Loeffler M . International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol. 1999; 17(1):423-9. DOI: 10.1200/JCO.1999.17.1.423. View

Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H . A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol. 2002; 68(6):354-61. DOI: 10.1034/j.1600-0609.2002.01654.x. View

10.

Nagata S . Apoptosis by death factor. Cell. 1997; 88(3):355-65. DOI: 10.1016/s0092-8674(00)81874-7. View

11.

Martelli M, Gherlinzoni F, De Renzo A, Zinzani P, De Vivo A, Cantonetti M . Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003; 21(7):1255-62. DOI: 10.1200/JCO.2003.01.117. View

12.

Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y . Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol. 2003; 130(2):107-13. DOI: 10.1007/s00432-003-0508-9. View

13.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

14.

Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C . Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004; 350(13):1287-95. DOI: 10.1056/NEJMoa031770. View

15.

Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P . Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(3):1131-7. DOI: 10.1200/JCO.1997.15.3.1131. View

16.

Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M . Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol. 2000; 64(4):257-61. DOI: 10.1002/1096-8652(200008)64:4<257::aid-ajh4>3.0.co;2-2. View

17.

Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S . Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood. 2001; 97(5):1202-10. DOI: 10.1182/blood.v97.5.1202. View

18.

Fisher R, Shah P . Current trends in large cell lymphoma. Leukemia. 2003; 17(10):1948-60. DOI: 10.1038/sj.leu.2403096. View

19.

Sehn L, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2006; 109(5):1857-61. DOI: 10.1182/blood-2006-08-038257. View

20.

Papoff G, Cascino I, Eramo A, Starace G, Lynch D, Ruberti G . An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol. 1996; 156(12):4622-30. View